Trials / Recruiting
RecruitingNCT06267183
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- Shanghai Synvida Biotechnology Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SV001 | SV001 ： single-dose |
| DRUG | Placebo | Placebo ： single-dose |
Timeline
- Start date
- 2024-01-12
- Primary completion
- 2026-11-30
- Completion
- 2026-12-30
- First posted
- 2024-02-20
- Last updated
- 2026-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06267183. Inclusion in this directory is not an endorsement.